🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

48 results for “cart” Clear

  1. ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia, Adult B-Cell

    phase 2 mab active

    1 trial

  2. umbilical cord mesenchymal stem cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cartilage Damage

    phase 2 mab active

    1 trial

  3. Anti-CLL1 CART cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  4. CART19 cell and auto-HSCT

    Shenzhen Second People's Hospital

    Leukemia, Lymphocytic, Acute, B-Cell

    phase 1 mab active

    1 trial

  5. CART19 cells effects in patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.

    The George Institute

    Relapsed/refractory CD19+ Acute Lymphoblastic Leukaemia and Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  6. CARTmeso CART19

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 mab active

    1 trial

  7. Descartes 30

    Cartesian Therapeutics

    Acute Respiratory Distress Syndrome

    phase 1 mab terminated

    1 trial

  8. Descartes-08

    Cartesian Therapeutics

    Multiple Myeloma

    phase 1 mab terminated

    1 trial

  9. Descartes-15

    Cartesian Therapeutics

    Refractory Multiple Myeloma

    phase 1 small molecule terminated

    1 trial

  10. Descartes-25

    Cartesian Therapeutics

    Multiple Myeloma

    phase 1 small molecule terminated

    1 trial

  11. Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Relapsed/Refractory B-cell non-Hodgkin lymphoma (r/r NHL)

    phase 1 small molecule active

    1 trial

  12. ThisCART19A

    The First People's Hospital of Lianyungang

    Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

  13. ThisCART19A

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Autoimmune Hemolytic Anemia

    phase 1 mab active

    1 trial

  14. ThisCART19A with Dose Level 1

    The First People's Hospital of Lianyungang

    CAR

    phase 1 small molecule active

    1 trial

  15. ThisCART22 cells injection

    The First People's Hospital of Lianyungang

    B Cell Malignancy

    phase 1 mab active

    1 trial

  16. ThisCART7 cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  17. autologous ET1402L1-CART cells

    AEON Biopharma

    Hepatocellular Carcinoma

    phase 1 mab terminated

    1 trial

  18. uCD7 CART

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia (AML)

    phase 1 mab active

    1 trial

  19. Elucirem 0.5 mmol/mL solution for injection, Gadovist 1.0 mmol/ml solution for injection in prefilled cartridge

    The George Institute

    Perianal fistula associated with Crohn's disease

    approved small molecule active

    1 trial

  20. Lantus 100 units/ml solution for injection in a cartridge, Lantus 100 units/ml solution for injection in a vial, Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Levemir FlexPen 100 units/ml solution for injection in pre-filled pen., Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Tresiba 200 units/mL FlexTouch solution for injection in pre-filled pen, Tresiba 100 units/mL FlexTouch solution

    NovoThirteen

    Type 2 diabetes

    approved small molecule active

    1 trial

  21. Levobupivacaína Normon 5 mg/ml solución inyectable y para perfusión EFG, Inibsacain 5 mg/ml + 0,005 mg/ml solución inyectable en cartucho

    The George Institute

    Hip fracture

    approved small molecule active

    1 trial

  22. Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Autoimmune Diseases

    small molecule active

    1 trial

  23. BCMA-CART

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    mab terminated

    1 trial

  24. PD1-BCMA-CART

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources